Quick answers
- What is Diphenoxylate hydrochloride and atropine sulfate used for?
- The FDA-approved label (Diphenoxylate Hydrochloride and Atropine Sulfate, Mylan Pharmaceuticals Inc., February 23, 2026) says: “Diphenoxylate hydrochloride and atropine sulfate is indicated as adjunctive therapy in the management of diarrhea in patients 13 years of age and older.” This page is not medical advice. Talk to your doctor or pharmacist before you start, stop or change any medicine.
- What are the side effects of Diphenoxylate hydrochloride and atropine sulfate?
- The “Adverse Reactions” section of the FDA label (Diphenoxylate Hydrochloride and Atropine Sulfate, Mylan Pharmaceuticals Inc., February 23, 2026) begins: “The following serious adverse reactions are described elsewhere in labeling: • Respiratory and/or CNS depression (see WARNINGS) • Anticholinergic and opioid-toxicities, including atroponism (see WARNINGS and PRECAUTIONS) • Dehydration and electrolyte imbalance (see WARNINGS) • GI Complications in patients with infectious diarrhea (see WARNINGS) • Toxic megacolon in patients with acute ulcerative colitis (see WARNINGS) At therapeutic doses of diphenoxylate hydrochloride and …” … This page is not medical advice. Talk to your doctor or pharmacist before you start, stop or change any medicine.
- What are the drug interactions of Diphenoxylate hydrochloride and atropine sulfate?
- The “Drug Interactions” section of the FDA label (Diphenoxylate Hydrochloride and Atropine Sulfate, Mylan Pharmaceuticals Inc., February 23, 2026) begins: “Alcohol Alcohol may increase the CNS depressant effects of diphenoxylate hydrochloride and atropine sulfate and may cause drowsiness (see WARNINGS). Avoid concomitant use of diphenoxylate hydrochloride and atropine sulfate with alcohol.” … This page is not medical advice. Talk to your doctor or pharmacist before you start, stop or change any medicine.
- Does Diphenoxylate hydrochloride and atropine sulfate have a boxed warning?
- No. None of the 28 FDA labels we found for this medicine has a boxed warning.
- Is there a shortage of Diphenoxylate hydrochloride and atropine sulfate?
- No current shortage is listed by the FDA for the products of this medicine (FDA data from November 13, 2026).
- Has Diphenoxylate hydrochloride and atropine sulfate been recalled?
- FDA enforcement reports list 1 recall of products of this medicine; the newest started October 20, 2017 (Class I). A recall usually concerns specific lots, not every product.
- Who makes Diphenoxylate hydrochloride and atropine sulfate?
- 21 companies list prescription products of Diphenoxylate hydrochloride and atropine sulfate in the FDA NDC Directory, including Aphena Pharma Solutions - Tennessee, LLC, A-S Medication Solutions and Bryant Ranch Prepack.
What Diphenoxylate hydrochloride and atropine sulfate is used for
Quoted from the “Indications and Usage” section of the FDA-approved label.
Diphenoxylate hydrochloride and atropine sulfate is indicated as adjunctive therapy in the management of diarrhea in patients 13 years of age and older.
— FDA label: Diphenoxylate Hydrochloride and Atropine Sulfate, Mylan Pharmaceuticals Inc., effective February 23, 2026. Read the full label on DailyMed →
Label quoted: the one for the most common form (tablet, oral), Diphenoxylate Hydrochloride and Atropine Sulfate, Mylan Pharmaceuticals Inc.; it covers 1 product in the FDA NDC Directory. The side effects, interactions, dosage and pregnancy quotes below come from this same label.
The FDA has 28 labels for products of this medicine (different makers and forms); uses can differ between them. Check the label that comes with your own medicine.
This page is not medical advice. Talk to your doctor or pharmacist before you start, stop or change any medicine.
Boxed warning
A boxed warning (“black box”) is the FDA’s strongest warning on a drug label, for serious or life-threatening risks.
The label quoted above has no boxed warning.
0 of 28 FDA labels for this medicine have a boxed warning.
Diphenoxylate hydrochloride and atropine sulfate side effects
Quoted from the “Adverse Reactions” section of the FDA-approved label. Tell your doctor about any side effect that worries you.
The following serious adverse reactions are described elsewhere in labeling:
- Respiratory and/or CNS depression (see WARNINGS)
- Anticholinergic and opioid-toxicities, including atroponism (see WARNINGS and PRECAUTIONS)
- Dehydration and electrolyte imbalance (see WARNINGS)
- GI Complications in patients with infectious diarrhea (see WARNINGS)
- Toxic megacolon in patients with acute ulcerative colitis (see WARNINGS) At therapeutic doses of diphenoxylate hydrochloride and …
— FDA label: Diphenoxylate Hydrochloride and Atropine Sulfate, Mylan Pharmaceuticals Inc., effective February 23, 2026. This is part of the section. Read the full label on DailyMed →
Diphenoxylate hydrochloride and atropine sulfate drug interactions
Quoted from the “Drug Interactions” section of the FDA-approved label. Tell your pharmacist about every medicine, vitamin and herbal product you take.
Alcohol Alcohol may increase the CNS depressant effects of diphenoxylate hydrochloride and atropine sulfate and may cause drowsiness (see WARNINGS). Avoid concomitant use of diphenoxylate hydrochloride and atropine sulfate with alcohol.
Read more of this section
Other Drugs that Cause CNS Depression The concurrent use of diphenoxylate hydrochloride and atropine sulfate with other drugs that cause CNS depression (e.g., barbiturates, benzodiazepines, opioids, buspirone, antihistamines, muscle relaxants), may potentiate the effects of diphenoxylate hydrochloride and atropine sulfate (see WARNINGS). Either diphenoxylate hydrochloride and atropine sulfate or the other interacting drug should be chosen, depending on the importance of the drug to the patient. If CNS-acting drugs cannot be avoided, monitor patients for CNS adverse reactions. MAO Inhibitors Diphenoxylate may interact with monoamine oxidase inhibitors (MAOIs) and precipitate a hypertensive crisis. Avoid use of diphenoxylate hydrochloride and atropine sulfate in patients who take MAOIs and monitor for signs and symptoms of hypertensive crisis (headache, hyperthermia, hypertension).
— FDA label: Diphenoxylate Hydrochloride and Atropine Sulfate, Mylan Pharmaceuticals Inc., effective February 23, 2026. Read the full label on DailyMed →
Diphenoxylate hydrochloride and atropine sulfate dosage
Quoted from the “Dosage and Administration” section of the FDA-approved label. Your own dose is the one your doctor prescribes: do not change it on your own.
Management of Diarrhea in Patients 13 Years of Age and Older Diphenoxylate hydrochloride and atropine sulfate is recommended as adjunctive therapy for the management of diarrhea in patients 13 years of age and older. Consider the nutritional status and degree of dehydration in patients prior to initiating therapy with diphenoxylate hydrochloride and atropine sulfate.
Read more of this section
The use of diphenoxylate hydrochloride and atropine sulfate should be accompanied by appropriate fluid and electrolyte therapy, when indicated. If severe dehydration or electrolyte imbalance is present, do not administer diphenoxylate hydrochloride and atropine sulfate until appropriate corrective therapy has been indicated (see WARNINGS). Initial and Maximum Recommended Dosage in Patients 13 Years of Age and Older The initial adult dosage is 2 diphenoxylate hydrochloride and atropine sulfate tablets four times daily (maximum total daily dose of 20 mg per day of diphenoxylate hydrochloride). Most patients will require this dosage until initial control of diarrhea has been achieved. Clinical improvement of acute diarrhea is usually observed within 48 hours. Dosage after Initial Control of Diarrhea After initial control has been achieved, the diphenoxylate hydrochloride and atropine sulfate dosage may be reduced to meet individual requirements. Control may often be maintained with as little as two diphenoxylate hydrochloride and atropine sulfate tablets daily. Duration of Treatment If clinical improvement of chronic diarrhea after treatment with the maximum recommended daily dosage is not observed within 10 days, discontinue diphenoxylate hydrochloride and atropine sulfate as symptoms are unlikely to be controlled by further administration.
— FDA label: Diphenoxylate Hydrochloride and Atropine Sulfate, Mylan Pharmaceuticals Inc., effective February 23, 2026. Read the full label on DailyMed →
Diphenoxylate hydrochloride and atropine sulfate in pregnancy
Quoted from the pregnancy part of the FDA-approved label. Ask your doctor before you take any medicine while pregnant or planning a pregnancy.
Diphenoxylate hydrochloride has been shown to have an effect on fertility in rats when given in doses 50 times the human dose (see above discussion). Other findings in this study include a decrease in maternal weight gain of 30% at 20 mg/kg/day and of 10% at 4 mg/kg/day. At 10 times the human dose (4 mg/kg/day), average litter size was slightly reduced.
Read more of this section
Teratology studies were conducted in rats, rabbits, and mice with diphenoxylate hydrochloride at oral doses of 0.4 to 20 mg/kg/day. Due to experimental design and small numbers of litters, embryotoxic, fetotoxic, or teratogenic effects cannot be adequately assessed. However, examination of the available fetuses did not reveal any indication of teratogenicity. There are no adequate and well-controlled studies in pregnant women. Diphenoxylate hydrochloride and atropine sulfate should be used during pregnancy only if the anticipated benefit justifies the potential risk to the fetus.
— FDA label: Diphenoxylate Hydrochloride and Atropine Sulfate, Mylan Pharmaceuticals Inc., effective February 23, 2026. Read the full label on DailyMed →
Diphenoxylate hydrochloride and atropine sulfate and breastfeeding
Quoted from the nursing mothers / lactation part of the FDA-approved label.
Caution should be exercised when diphenoxylate hydrochloride and atropine sulfate is administered to a nursing woman, since the physicochemical characteristics of the major metabolite, diphenoxylic acid, are such that it may be excreted in breast milk and since it is known that atropine is excreted in breast milk.
— FDA label: Diphenoxylate Hydrochloride and Atropine Sulfate, Mylan Pharmaceuticals Inc., effective February 23, 2026. Read the full label on DailyMed →
When Diphenoxylate hydrochloride and atropine sulfate should not be used
Quoted from the “Contraindications” section of the FDA-approved label.
Diphenoxylate hydrochloride and atropine sulfate is contraindicated in:
- Pediatric patients less than 6 years of age due to the risks of respiratory and central nervous system (CNS) depression (see WARNINGS).
- Patients with diarrhea associated with pseudomembranous enterocolitis (Clostridium difficile) or other enterotoxin-producing bacteria due to the risk of gastrointestinal (GI) complications, including sepsis (see WARNINGS).
Read more of this section
- Patients with known hypersensitivity to diphenoxylate or atropine.
- Patients with obstructive jaundice.
— FDA label: Diphenoxylate Hydrochloride and Atropine Sulfate, Mylan Pharmaceuticals Inc., effective February 23, 2026. Read the full label on DailyMed →
Diphenoxylate hydrochloride and atropine sulfate overdose
Quoted from the “Overdosage” section of the FDA-approved label. If someone may have taken too much, call Poison Help at 1-800-222-1222 (or 911 in an emergency).
Diagnosis Overdosage can be life-threatening. Symptoms of overdosage may include opioid and/or anticholinergic effects including respiratory depression, coma, delirium, lethargy, dryness of the skin and mucous membranes, mydriasis or miosis, flushing, hyperthermia, tachycardia, hypotonia, tachypnea, toxic encephalopathy, seizures and incoherent speech.
Read more of this section
Respiratory depression has been reported up to 30 hours after ingestion and may recur despite an initial response to narcotic antagonists. Treat all possible diphenoxylate hydrochloride and atropine sulfate overdosages as serious and maintain medical observation/hospitalization until patients become asymptomatic without naloxone use. Treatment A pure narcotic antagonist (e.g., naloxone) should be used in the treatment of respiratory depression caused by diphenoxylate hydrochloride and atropine sulfate. Refer to the prescribing information for naloxone. Consider diphenoxylate hydrochloride and atropine sulfate toxicity even in settings of negative toxicology tests. Following initial improvement of respiratory function, repeated doses of naloxone hydrochloride may be required to counteract recurrent respiratory depression. If over-exposure occurs, call your Poison Control Center at 1-800-222-1222 for current information on the management of poisoning or overdosage.
— FDA label: Diphenoxylate Hydrochloride and Atropine Sulfate, Mylan Pharmaceuticals Inc., effective February 23, 2026. Read the full label on DailyMed →
Forms and how it is given
| Dosage forms | Tablet · Solution |
|---|---|
| Route | Oral |
| Prescription products | 28 in the FDA NDC Directory |
| Brand names | Lomotil |
What pharmacies pay (NADAC)
The National Average Drug Acquisition Cost (NADAC) is the average price U.S. retail pharmacies paid to buy one unit of a medicine (one tablet, one mL or one gram), from a monthly survey of pharmacy invoices by the Centers for Medicare & Medicaid Services (CMS). State Medicaid programs use it to pay pharmacies.
This is not the price you pay. What you pay depends on your insurance (copay or coinsurance), your pharmacy and any discounts, and pharmacies also charge for filling a prescription. Ask your pharmacist or your health plan what your price will be.
| Strength and form | Generic or brand | Pharmacies pay |
|---|---|---|
| atropine sulfate 0.025 mg · diphenoxylate hydrochloride 2.5 mg tablet | Generic | $0.1428 per tablet |
| atropine sulfate 0.025 mg · diphenoxylate hydrochloride 2.5 mg tablet | Brand: Lomotil | $2.99 per tablet |
NADAC list of November 11, 2026; these prices took effect on October 21, 2026. Shown only where a package’s NDC code matches the NADAC list exactly, and only for that exact strength and form: nothing is averaged across strengths. Strengths and forms not listed here have no NADAC price.
Source: NADAC (National Average Drug Acquisition Cost) 2026, data.medicaid.gov (CMS) →
Companies that list this medicine
Labelers in the FDA NDC Directory: the company named on the package (maker or distributor), with the number of prescription products.
- Aphena Pharma Solutions - Tennessee, LLC4 products
- A-S Medication Solutions3 products
- Bryant Ranch Prepack2 products
- Proficient Rx LP2 products
- Unichem Pharmaceuticals (USA), Inc.1 product
- RedPharm Drug, Inc.1 product
- Direct_Rx1 product
- NuCare Pharmaceuticals, Inc.1 product
- Preferred Pharmaceuticals Inc.1 product
- Winder Laboratories LLC1 product
- Redpharm Drug1 product
- Remedyrepack Inc.1 product
- Mylan Pharmaceuticals Inc.1 product
- Leading Pharma, LLC1 product
- PD-Rx Pharmaceuticals, Inc.1 product
- Pfizer Laboratories Div Pfizer Inc1 product
- Chartwell RX, LLC1 product
- American Health Packaging1 product
- Hikma Pharmaceuticals USA Inc.1 product
- ANI Pharmaceuticals, Inc.1 product
- SpecGx LLC1 product
FDA approval history
- NDA: New Drug Application: how a new (usually brand-name) medicine is approved.
- ANDA: Abbreviated New Drug Application: how a generic version is approved.
| Application | Sponsor | Approved | Later changes approved |
|---|---|---|---|
| NDA012462 LOMOTIL | Pfizer | September 15, 1960 | 19, latest February 12, 2018 2018: Labeling · 2017: Labeling · 2006: Labeling |
Generic approvals (7)
- ANDA086727Ani Pharms · October 29, 1979
- ANDA087708Hikma · May 3, 1982
- ANDA210819Unichem · November 13, 2018
- ANDA213413Leading · February 20, 2020
- ANDA213335Specgx LLC · October 6, 2020
- ANDA207128Chartwell Rx · October 21, 2020
- ANDA211362Winder Labs LLC · January 27, 2021
Shortage status
The FDA drug shortage list does not show these products.
Recalls
From FDA enforcement reports, matched by the product’s NDC code. A recall usually covers specific lots only: check the lot number on your package and ask your pharmacist. Do not stop a medicine on your own.
-
October 20, 2017 · Class I · Terminated · D-0150-2018
SUPERPOTENT: Weight variations resulting in tablets that are sub and super potent
diphenoxylate hydrochloride and atropine sulfate tablets, USP, 2.5 mg/0.025 mg, a) 100-count bottle (NDC 59762-1061-1), b) 1000-count bottle (NDC 59762-1061-2), Rx Only, Distributed by: Greenstone LLC. Peapack, NJ 07977 — Pfizer Inc.
What do the recall classes mean?
Class I: The most serious type: there is a reasonable chance that using the product will cause serious health problems or death.
Class II: Using the product may cause temporary or medically reversible health problems, or the chance of serious problems is remote.
Class III: Using the product is not likely to cause health problems (for example a labeling or packaging issue).
Official identifiers
| RxCUI (RxNorm) | 1190568, 1190572, 1190641 |
|---|---|
| SPL set ID of the quoted label | 83bcc2fb-6fb0-4f0e-8e66-592d327684ec |
| FDA labels (SPL) | 28 |
| FDA applications | NDA012462, 7 ANDA |
| Active ingredients (FDA) | ATROPINE / DIPHENOXYLATE |
Next steps
- Find a pharmacy near youAsk which price applies to you and whether your product is affected by a recall
- Latest FDA drug recallsAll medicines, newest first
- LomotilBrand page: products, maker and price
- Aphena Pharma Solutions - Tennessee, LLCMaker or distributor
- A-S Medication SolutionsMaker or distributor
- Bryant Ranch PrepackMaker or distributor
- All prescription drugs A to ZSearch by generic, brand or Spanish name
Sources
- FDA-approved label on DailyMed (National Library of Medicine) — Diphenoxylate Hydrochloride and Atropine Sulfate, Mylan Pharmaceuticals Inc., effective February 23, 2026; via openFDA, FDA data exported November 13, 2026, retrieved November 14, 2026
- NDC Directory (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported November 13, 2026, retrieved November 14, 2026
- Drugs@FDA (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported November 13, 2026, retrieved November 14, 2026
- Drug recall enforcement reports (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported November 10, 2026, retrieved November 14, 2026
- Drug shortages (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported November 13, 2026, retrieved November 14, 2026
openFDA data is provided by the FDA as is; it may be incomplete. Always rely on the label that comes with your medicine. FDA Enforcement Report search →